ALIGN (2025) — Trial Summary

ALIGN (2025): The ALIGN phase 3 trial evaluated atrasentan, a selective endothelin type A receptor antagonist, versus placebo in patients with IgA nephropathy at risk of progressive kidney function loss, building on the earlier phase 2 APPLAUSE-IgAN results.

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.